AngioDynamics Inc. has announced its plan to launch a new varicose vein therapy brand, VenaCure EVLT. The new brand will encompass the best of AngioDynamics’ VenaCure(R) product line as well as EVLT(R), a product line which AngioDynamics recently rescued from the bankruptcy of Diomed Inc. The product is an outpatient alternative to otherwise painful and invasive surgery for patients. VenaCure EVLT provides physicians continuous support from AngioDynamics to develop their clinical practices and provide patients with the best treatment available.

The U.S. Food and Drug Administration has approved CV Therapeutics’ Ranexa (ranolazine) for treating chronic angina. The changed labeling also informs that Ranexa showed better results for conditions like arrhythmias, new onset atrial fibrillation and bradycardia (dangerously slow heartbeat in patients of coronary artery disease). Also, the labeling mentions that Ranexa lowers hemoglobin A1c (HbA1c) in diabetes patients. The drug can now be used as a part of optimal therapy. Neither it reduces heart rate nor blood pressure. Unlike other long acting nitrates, Ranexa is prescribed for patients taking oral treatments for erectile dysfunction.

The U.S. Food and Drug Administration has approved Sanofi-aventis’ Apidra (insulin glulisine injection) to recover glycemic control in children above the age of 4 years suffering from diabetes mellitus. The approval for pediatric use of the injection is based upon FDA’s review of a 6 month long phase III study involving 572 children with type 1 diabetes. Apidra(R), having a rapid onset and shorter period of action, should normally be used along with a basal insulin with a longer duration of action. The product can also be applied in insulin infusion pump treatment for controlling blood sugar.

The U.S. Food and Drug Administration has approved Duramed Pharmaceuticals’ LoSEASONIQUE(R) extended-cycle oral contraceptive. The product is the first lower-dose, extended-cycle oral contraceptive approved for the prevention of pregnancy. The LoSEASONIQUE(R) regimen requires women to take combination tablets for 84 consecutive days, followed by 0.01 mg ethinyl estradiol tablets for a week. The treatment reduces the periods of withdrawal bleeding to four from 13 per year.

The U.S. Food and Drug Administration has approved Astellas Pharma US, Inc.’s new Vaprisol (conivaptan hydrochloride injection) premixed in 5% Dextrose. An arginine vasopressin (AVP) receptor antagonist, Vaprisol is the only drug approved and indicated for use in the treatment of patients with either kind of hyponatremia – euvolemic or hypervolemic. Its single-use (100ml) premixed formulation is available in an INTRAVIA(R) Container. The latest formulation will simplify preparation as it requires no mixing or measuring. Its safe usage period is six months longer than the original ampule formulation.

Meda’s new Astepro Nasal Spray (an improvement of the already available Astelin) has received the approval of the U.S. Food and Drug Administration. The new product is better tolerated by patients, caused lesser discomfort and was not tha bitter too. On the other hand,  relief from symptoms improved. Azelastine, the nasal antihistamine used for treating rhinitis is the active substance in it.

The U.S. Food and Drug Administration  has approved Bayer HealthCare’s Kogenate(R) FS for routine prophylaxis in children suffering from hemophilia. The drug will be used to reduce the incidence of joint damage and lower the frequency of bleeding episodes in patients below the age of 16 years. The approval makes Kogenate(R) FS the only factor VIII treatment regarded as safe and effective for routine prophylaxis by the FDA.The study on which the approval is based had special emphasis on index joints like elbow, knee and ankle that are most prone to bleeding.

The European Medicines Agency has granted approval to OMRIX Biopharmaceuticals, Inc.’s liquid fibrin sealant, Evicel. The product can now be marketed in Europe for supportive therapy in surgery for hemostasis. It is currently sold in the US markets by a Johnson & Johnson division. EVICEL, with this approval, is licensed for commercialization in the 27 countries coming under the European Union. This easy and ready to use liquid does not contain aprotinin, preventing any adverse effects.

The U.S. Food and Drug Administration has given the approval to Watson Pharmaceuticals, Inc.’s RAPAFLO(TM) (silodosin), the novel alpha blocker to be used for treating the symptoms of Benign Prostatic Hyperplasia (BPH). The disorder is characterized by prostate problems such as decline in urine flow, nocturia and frequent urination. RAPAFLO binds to the alpha (1A) receptors, with high affinity, that are concentrated in the prostate. This smoothens the muscles in these tissues. As they get to relax, urine flow improves.

Aclasta, the drug manufactured by Novartis for the treatment of osteoporosis has received approval from the European Commission for use in men facing a high risk of fractures. Along with that, the Aclasta label has been broadened by EU to include reduction of new clinical fractures in men as well as post-menopausal women suffering from osteoporosis, who had a hip fracture recently. Known as Reclast in the United States, the once-yearly drug belongs to the category of medicines called bisphosphonates that boost bone mass, reducing fracture risk in osteoporosis patients.